Share Name Share Symbol Market Type
PolyPid Ltd NASDAQ:PYPD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.75 4.52% 17.33 16.56 22.60 17.8403 16.60 16.78 71,682 01:00:00

PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sh...

30/06/2020 9:01pm

PR Newswire (US)

Historical Stock Chart

From Jun 2020 to Jul 2020

Click Here for more PolyPid Charts.

PETAH TIKVA, Israel, June 30, 2020 /PRNewswire/ -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the closing of its initial public offering of 4,312,500 ordinary shares, including the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $16.00 per share, for gross proceeds of $69.0 million. The shares are listed for trading on the Nasdaq Global Market under the symbol "PYPD."

PolyPid Ltd Logo (PRNewsfoto/PolyPid Ltd.)

Barclays and BMO Capital Markets acted as joint book-running managers. Raymond James acted as lead manager. National Securities Corporation, ODDO BHF and A.G.P/Alliance Global Partners acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 25, 2020. The offering was made only by means of a prospectus, copies of which may be obtained from Barclays Capital Inc. c/o Broadridge Financial Solutions by mail at 1155 Long Island Avenue, Edgewood, NY, 11717, by email at, or by calling 888-603-5847 or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, New York 10036, telephone: 1-800-414-3627 or by emailing

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Company contacts:
PolyPid, Ltd. 
Dikla Czaczkes Akselbrad
Chief Financial Officer
Tel: +972-747195700

Cision View original content to download multimedia:

SOURCE PolyPid Ltd.

Copyright 2020 PR Newswire

1 Year PolyPid Chart

1 Year PolyPid Chart

1 Month PolyPid Chart

1 Month PolyPid Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200703 17:19:20